



ProstaLund signs distribution agreement for Poland

ProstaLund AB has signed an exclusive distribution agreement with the Polish company Meden-Inmed Sp. z o.o. The agreement is expected to generate revenues of at least SEK 0.5 million until the end of 2024.

Last year, the internationalization process to countries outside the Nordic region started and ProstaLund signed distribution agreements for a couple of countries within Europe: UK, Spain, Italy. Next country in line is Poland where a distribution agreement with Meden-Inmed has been signed.

Meden-Inmed is a major producer and a distributor of professional medical facilities across Poland and is already the exclusive distributor in Poland for a range of urology products, including Boston Scientific's Rezūm™, to treat benign prostatic hyperplasia. With the help of ProstaLund's devices, Meden-Inmeds existing customers can now be offered a holistic concept where treatments can be performed under safe and effective local anesthesia (Schelin Catheter®) and patients can be offered a more comfortable alternative to indwelling catheters (CoreFlow® Soft Stent).

Last week, ProstaLund and Meden-Inmed together introduced the Schelin Catheter and CoreFlow – Soft Stent to a first clinic in Wrocław with very good outcome. The now established partnership between ProstaLund and Meden-Inmed enables the introduction to be significantly accelerated in Poland.

"We believe the high-quality devices from ProstaLund have a big potential in the Polish market and the devices will enhance our possibilities to grow our current business.", comments CEO Maciej Zinka.

"Seeing is believing. After the initial very good experience last week, I am pretty sure that our collaboration with Meden-Inmed will succeed in exploring the potential of both Schelin Catheter and CoreFlow in Poland. ", says CEO Johan Wennerholm in a comment.

**Rezūm™ is trademark owned by Boston Scientific Inc. Rezūm™ is not marketed or sold by ProstaLund and there is no commercial connection between the companies.*

For further information, please contact:

Johan Wennerholm, CEO
Tel. +46 (0) 730 429997
Email: johan.wennerholm@prostalund.com



PRESS RELEASE
25 April 2023 10:15:00 CEST

About ProstaLund

ProstaLund AB is a Swedish medical technology company and a leading developer and manufacturer of innovative urological devices and treatments. The company's lead product, CoreTherm, is a patented Thermotherapy treatment method for Benign Prostatic Hyperplasia (BPH) which can be tailored to suit the needs of each individual patient. CoreTherm is used today in hospitals and clinics in Sweden and worldwide. ProstaLund is listed on the Nasdaq First North Growth Market.

Certified Adviser:

Västra Hamnen Corporate Finance AB

Phone: +46 40 200 250

E-mail: ca@vhcorp.se

This information is information that ProstaLund AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-04-25 10:15 CEST.

Attachments

ProstaLund signs distribution agreement for Poland